03 March 2023 : Original article
Comparison of Biosimilar Filgrastim with Innovator Fligrastim for Peripheral Blood Stem Cells Mobilization, Collection of CD34+ Stem Cells, and Engraftment in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation: A Single-Center Experience
Maha M. Islami






DOI: 10.12659/AOT.938585
Ann Transplant 2023; 28:e938585
Table 2 Mobilization results.
Parameters | Zarzio® | Neupogen® | P value | |
---|---|---|---|---|
Autologous | Time to successful harvest | |||
Filgrastim + chemotherapy | 14 | 15 | 0.477 | |
Filgrastim | 5 | 5 | 0.657 | |
CD34+ ×10/kg | ||||
Filgrastim + chemotherapy | 5 | 5.5 | 0.641 | |
Filgrastim | 3.76 | 4.44 | 0.214 | |
Allogeneic (healthy donors) | Time to successful harvest | 4 | 4 | 0.576 |
CD34+ ×10/kg | 6.445 | 6 | 0.347 |